The Justice Department has resolved its probe of Alibaba and AUS Merchant Services Inc. with a $600 million settlement and a non-prosecution agreement, ending a case that prosecutors believed could support felony violations of the Food, Drug and Cosmetic Act. Under the deal, the companies admitted only to lesser misdemeanor violations.
That resolution matters now because the case touched public health as well as corporate enforcement. Investigators said the companies failed for eight years to stop dangerous drugs, chemicals and pill presses from being sold to American customers, even as employees warned about compliance problems. Career prosecutors had urged a deferred prosecution agreement, a stricter option that would have kept the case alive under court oversight, but Justice Department leadership chose a lighter path.
The timeline helps explain why the decision is drawing attention. The case began during President Trump’s first administration, then grew stronger during the Biden administration after a senior official in then-Deputy Attorney General Lisa Monaco’s office urged staff to keep digging instead of settling quickly. By the time it was resolved, prosecutors reportedly believed they had enough evidence to prove felony violations, which made the final outcome feel, to critics, like a retreat from the case the government itself had built.
The Food, Drug and Cosmetic Act gives prosecutors a wide reach over counterfeit, adulterated or misbranded drugs and medical devices, along with food, supplements and cosmetics. In this case, the government said the evidence showed that line had been crossed through a long-running failure to block dangerous goods from reaching American buyers. The Justice Department also said it does not believe in regulation by prosecution, signaling that it sees criminal cases as a backstop rather than the main tool for oversight.
Lisa Gilbert, who has pressed the administration on corporate accountability, said President Trump talks about being tough on crime while his administration cuts enforcement for corporate law-breakers. She also said that when Americans’ health and safety are at stake, withholding accountability has real-life consequences. Her criticism lands on the sharpest part of the deal: the government collected a large financial penalty, but it stopped short of the kind of felony case prosecutors thought they could prove.
That is why this resolution may be remembered less for the size of the penalty than for the choice behind it. The Justice Department says it protected the public interest without turning enforcement into regulation by prosecution. Critics see something else — a case with evidence strong enough to push farther, settled before it reached that point. What comes next is not another filing on the calendar, but the question of how far the government is willing to go when the next corporate health case is ready for trial.
